| Drug Name: | Codeine (76-57-3) |
|---|---|
| PubChem ID: | 5284371 |
| SMILES: | CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3[C@H](C=C4)O |
| InchiKey: | OROGSEYTTFOCAN-DNJOTXNNSA-N |
| Therapeutic Category: | Analgesics, Antitussive Agents, Central Nervous System Agents, Central Nervous System Depressants, Narcotics, Peripheral Nervous System Agents, Respiratory System Agents, Sensory System Agents |
| Molecular Weight (dalton) | : | 299.37 |
| LogP | : | 1.5011 |
| Ring Count | : | 1 |
| Hydrogen Bond Acceptor Count | : | 4 |
| Hydrogen Bond Donor Count | : | 1 |
| Total Polar Surface Area | : | 41.93 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|---|---|---|---|
| Glutethimide (77-21-4) | Psychosis | Additive | Not Known | The study of codeine-gluthetimide pharmacokinetic interaction in rats |
| Lanreotide (108736-35-2) | Analgesic Effect Decreased | Antagonistic | Reduction in O-demethylation can reduce the active metabolite of codeine, which could reduce the analgesic effect of the drug. | Selective effects of somatostatin analogs on human drug-metabolizing enzymes |
| Quinidine (56-54-2) | Analgesic Effect Decreased | Antagonistic | The conversion of codeine to its active analgesic metabolite in the body depends upon the activity of the cytochrome P450 isoenzyme CYP2D6 in the liver. This isoenzyme is inhibited by quinidine, these conversions largely fail to occur and the analgesic effects are reduced or lost | The effect of quinidine on the analgesic effect of codeine |
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|---|---|---|
| Increasing Cns Depression | CYP2D6 (P10635) | Narcotic analgesics@ alcohol@ general anesthetics@ tranquilizers such as chlordiazepoxide@ sedative-hypnotics@ or other CNS depressants@ causing increased CNS depression. [ ADR Type 4 ] | Comment: potential risk of valproic acid therapy in patients who are HIV-positive |
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category